Cardiff Oncology, Inc. (CRDF) Revenue History
Annual and quarterly revenue from 2005 to present
CRDF Revenue Over Time (2005–2025)
CRDF Revenue Growth History
9 of 16 years with positive growth- FY2005 revenue growth
- N/A
- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- -59.1%
- FY2011 revenue growth
- -3.0%
- FY2012 revenue growth
- +74.6%
- FY2013 revenue growth
- -42.4%
- FY2014 revenue growth
- +8.0%
- FY2015 revenue growth
- +11.8%
- FY2016 revenue growth
- +21.7%
- FY2017 revenue growth
- +32.5%
- FY2018 revenue growth
- -25.1%
- FY2019 revenue growth
- -35.3%
- FY2020 revenue growth
- +49.6%
- FY2021 revenue growth
- -1.9%
- FY2022 revenue growth
- +7.5%
- FY2023 revenue growth
- +26.4%
- FY2024 revenue growth
- +40.0%
- FY2025 revenue growth
- -13.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $41K | -62.4% |
| Q4 2025 | $243K | +60.9% |
| Q3 2025 | $120K | -27.3% |
| Q2 2025 | $121K | -25.8% |
| Q1 2025 | $109K | -46.8% |
| Q4 2024 | $151K | -3.2% |
| Q3 2024 | $165K | +17.0% |
| Q2 2024 | $163K | +50.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2020)
CRDF's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
CRDF Revenue Analysis (2005–2025)
Current Revenue & Growth
As of June 12, 2026, Cardiff Oncology, Inc. (CRDF) generated trailing twelve-month (TTM) revenue of $525,000, reflecting significant decline in growth of -62.4% year-over-year. The most recent quarter (Q1 2026) recorded $41,000 in revenue, down 83.1% sequentially.
Historical Growth Trajectory
CRDF's 5-year compound annual growth rate (CAGR) stands at +10.1%, indicating consistent double-digit revenue growth. The 3-year CAGR of +15.4% exceeds the 5-year average, indicating an acceleration in the most recent period. Cardiff Oncology, Inc.'s highest annual revenue of $683,000 was recorded in 2024.
Revenue by Segment
CRDF's revenue is primarily driven by Royalty (100%). With over half of revenue concentrated in Royalty, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including TGTX (+81.3% YoY), MGNX (+3.1% YoY), and NKTR (-36.2% YoY) — CRDF has underperformed the peer group in revenue growth. Compare CRDF vs TGTX →
CRDF Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 CRDFCurrent | $525,000 | -62.4% | +10.1% | -8256.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 KPTI | $146M | +6.3% | +6.2% | -62.1% |
CRDF Historical Revenue Data (2005–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $593K | -13.2% | $593K | 100.0% | $-48,960,000 | -8256.3% |
| 2024 | $683K | +40.0% | $683K | 100.0% | $-48,651,000 | -7123.1% |
| 2023 | $488K | +26.4% | $488K | 100.0% | $-45,412,000 | -9305.7% |
| 2022 | $386K | +7.5% | $386K | 100.0% | $-39,902,000 | -10337.3% |
| 2021 | $359K | -1.9% | $359K | 100.0% | $-28,855,000 | -8037.6% |
| 2020 | $366K | +49.6% | $366K | 100.0% | $-19,086,000 | -5214.8% |
| 2019 | $245K | -35.3% | $245K | 100.0% | $-16,678,494 | -6817.8% |
| 2018 | $378K | -25.1% | $-219,000 | -57.9% | $-17,053,000 | -4511.4% |
| 2017 | $505K | +32.5% | $-1,306,000 | -258.6% | $-25,596,000 | -5068.5% |
| 2016 | $381K | +21.7% | $-1,349,000 | -354.1% | $-40,145,000 | -10536.7% |
| 2015 | $313K | +11.8% | $-316,000 | -101.0% | $-25,274,000 | -8074.8% |
| 2014 | $280K | +8.0% | $265K | 94.6% | $-14,945,000 | -5337.5% |
| 2013 | $259K | -42.4% | $-3,222,205 | -1242.9% | $-10,690,541 | -4123.7% |
| 2012 | $450K | +74.6% | $-1,470,298 | -326.7% | $-4,849,000 | -1077.6% |
| 2011 | $258K | -3.0% | $258K | 100.0% | $-2,976,803 | -1155.2% |
What if you invested $1,000 in CRDF back in 2005?
Total return with dividends reinvested · 21+ years of data
Calculate ReturnsHow much would $100/month in CRDF be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CRDF Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCRDF vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowCRDF — Frequently Asked Questions
Quick answers to the most common questions about buying CRDF stock.
Is CRDF's revenue growth accelerating or slowing?
CRDF revenue is declining -62.4% year-over-year. TTM revenue fell to $525000.00, contrasting with the 5-year CAGR of +10.1%. The reversal reflects either macro headwinds or company-specific challenges.
What is CRDF's revenue history from 2005 to 2026?
Cardiff Oncology, Inc. (CRDF) revenue history spans 2005 to 2026. TTM revenue as of 2026 is $525000.00, growing at -62.4% YoY. The 5-year CAGR is +10.1%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CRDF's long-term revenue growth rate (CAGR)?
Cardiff Oncology, Inc.'s 5-year revenue CAGR of +10.1% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -62.4% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CRDF.
Why does CRDF's quarterly revenue fluctuate?
CRDF quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Cardiff Oncology, Inc.'s revenue data from 2005 to 2026 shows full historical quarterly detail on this page.
How is CRDF's revenue distributed by segment?
CRDF reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CRDF's revenue compare to industry peers?
Cardiff Oncology, Inc. (CRDF) with TTM revenue of $525000.00 and -62.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.